The Patent Finder

Harpoon Therapeutics, Inc.

23 patents currently held · Updated Nov 18, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 7, 2027
    The maintenance fee for DLL3 Binding Proteins and Methods of Use (US 11,807,692) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 2 fees due Jul 28, 2027
  • 1 fee due Nov 7, 2027
    The maintenance fee for B Cell Maturation Antigen Binding Proteins (US 11,976,125) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,708,412Trispecific binding proteins and methods of use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,920,115Single Domain Serum Albumin Binding Protein
In force
 · High confidence
In forceHigh confidence
US 10,066,016Single Chain Variable Fragment CD3 Binding Proteins
In force
 · Low confidence
In forceLow confidence
US 10,100,106Single Domain Serum Albumin Binding Protein
In force
 · High confidence
In forceHigh confidence
US 10,544,221Single Chain Variable Fragment CD3 Binding Proteins
In force
 · High confidence
In forceHigh confidence
US 11,453,716Single Domain Serum Albumin Binding Protein
In force
 · High confidence
In forceHigh confidence
US 11,623,958Single Chain Variable Fragment CD3 Binding Proteins
In force
 · Low confidence
In forceLow confidence
US 12,528,859Single Domain Serum Albumin Binding Protein
In force
 · Medium confidence
In forceMedium confidence
US 10,954,311Trispecific binding proteins and methods of use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,543,271Mesothelin binding proteins
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
Also on record, not counted in the 23: 1 patent in force now held by others · 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 2 abandoned · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited